Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
- Written by ACN Newswire - Press Releases
Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme,
Read more //?#
.
BizCover Brings Australia’s First AI-Based Insurance Quotes to ChatGPT
Australian small business owners can now receive and compare business insurance quotes directly inside ChatGPT, in a move that signals a major shi...
VistaPrint Research Reveals Australian Small Businesses Face a Succession Cliff
With only 16% of retiring small businesses having a succession plan, tens of thousands risk closure as one in three owners nears retirement. Ne...
Corporate volunteering grows up: how companies are shifting to meaningful, community-led impact
As workplaces settle into the new year and look for ways to strengthen culture, capability and connection, experts say corporate volunteering is e...
The Rise of Mobile-First Venues
Global Hospitality Platform, Tabit, Reveals Five Ways to Maximise Benefits of Mobile-First Systems As Australian hospitality venues grapple with...
Why the SME is now the primary engine of global cybercrime
For over a decade, the most practical and effective advice we could offer an employee was to spot the typo. It was practical, it was free, and it wo...
Work-life Balance Key to Solving Construction Talent Shortage
New data from leading talent company Randstad Australia shows flexible working and work-life balance could be critical to addressing ongoing talen...